CJC-1295 for Longevity and Anti-Aging: Protocol, Dosing, and What to Expect
Evidence strength: moderate
What this protocol is for
GH support for longevity is one of the more contested use cases in the peptide space. The mechanism is plausible: growth hormone declines steeply from the third decade onward, and the cellular processes that GH supports (lean tissue maintenance, sleep architecture, immune resilience, collagen turnover) all degrade in parallel. CJC-1295 elevates endogenous GH and IGF-1 toward levels typical of a younger pituitary curve. The case for whether this translates into longer healthspan, longer lifespan, or just better function at any given age is mechanism-driven; the longevity-specific clinical trials are limited.
The clinical pattern in user reports is consistent. Improved sleep architecture, particularly deeper slow-wave sleep. Better body composition over months. Faster recovery from training, illness, and minor injuries. Anecdotally, users report feeling biologically younger in functional terms (energy, sleep, recovery) over 12 to 16 weeks. The harder questions about cancer risk, IGF-1 elevation in midlife, and long-term safety remain open; this is not a settled protocol the way BPC-157 is for tissue work.
Used by many in the recovery / biohacking space as part of a multi-pronged longevity stack. Not as a standalone fountain-of-youth move. Run with a clinician who can monitor IGF-1 levels and pull the cord if anything drifts outside healthy range. This is a tactical, legal performance layer with caveats: the mechanism is real, the longevity-specific evidence is thinner, the monitoring matters.
Dose for longevity and anti-aging
CJC-1295 with DAC: 1 mg subcutaneous once weekly. Conservative dose for longevity protocols compared to muscle-gain (which typically uses 1 to 2 mg). The goal here is restoration toward a younger GH curve, not pharmacological elevation. Without DAC (Mod GRF 1-29): 100 mcg per dose, 1 to 2 times daily, often timed pre-sleep and pre-training.
Cycle length
12 to 16 weeks on, 4 to 6 weeks off, run 2 to 3 times per year. Longevity protocols favour the longer cycle because the cumulative benefit lands in months 3 to 4, not weeks. Continuous use beyond 16 weeks is not recommended; pituitary feedback adaptation degrades the signal.
Stack pairings
Commonly stacked with Ipamorelin.
Expected timeline
Week 1–4: sleep improvements show up first. Deeper slow-wave sleep, fewer mid-night wakings. Week 4–8: body composition shifts gradually toward more lean tissue, less visceral fat. Week 8–16: functional gains in recovery, energy, and training capacity. Bloodwork showing IGF-1 elevation typically lands by week 4 and stays elevated through the cycle.
Common mistakes
- Running CJC-1295 without IGF-1 monitoring. For longevity-focused protocols, bloodwork before, mid-cycle (week 6), and after matters more than for short hypertrophy cycles. IGF-1 in the upper-normal-for-age range is the target; pharmacological elevation is not.
- Ignoring the cancer-risk conversation. Elevated IGF-1 has a complex relationship with cancer risk. This is a discussion to have with a clinician, particularly for men with family history.
- Running it as a continuous protocol without cycling. The pituitary adapts. The signal degrades. Cycling preserves responsiveness.
- Stacking CJC with high-dose exogenous growth hormone. Doubling up on the same pathway is not the way to extend a longevity protocol. Pick one approach and run it cleanly.